Natera is a diagnostics company. Co. operates one segment, the development and commercialization of molecular testing services, applying its proprietary technology in the fields of women's health, oncology and organ health. Co.'s product offerings include: Panorama Non-Invasive Prenatal Test, which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother; Vistara, which is a single-gene mutations screening test performed to identify single-gene disorders; and Horizon Carrier Screening, which determines carrier status for a number of severe genetic diseases that could be passed on to the carrier's children. We show 30 historical shares outstanding datapoints in our coverage of NTRA's shares outstanding history.
Understanding the changing numbers of NTRA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NTRA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NTRA by allowing them to research NTRA shares outstanding history
as well as any other stock in our coverage universe. |
Free NTRA Email Alerts:
Video: Shares Outstanding Importance
